Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis
Hereditary transthyretin-mediated (hATTR) amyloidosis is a progressive, debilitating disease often resulting in early-onset, life-impacting autonomic dysfunction. The effect of the RNAi therapeutic, patisiran, on autonomic neuropathy manifestations in patients with hATTR amyloidosis with polyneuropa...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2020
|
| In: |
Journal of neurology
Year: 2019, Jahrgang: 267, Heft: 3, Pages: 703-712 |
| ISSN: | 1432-1459 |
| DOI: | 10.1007/s00415-019-09602-8 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00415-019-09602-8
|
| Verfasserangaben: | Alejandra González-Duarte, John L. Berk, Dianna Quan, Michelle L. Mauermann, Hartmut H. Schmidt, Michael Polydefkis, Márcia Waddington-Cruz, Mitsuharu Ueda, Isabel M. Conceição, Arnt V. Kristen, Teresa Coelho, Cécile A. Cauquil, Céline Tard, Madeline Merkel, Emre Aldinc, Jihong Chen, Marianne T. Sweetser, Jing Jing Wang, David Adams |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1693836785 | ||
| 003 | DE-627 | ||
| 005 | 20240405193211.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200402r20202019xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00415-019-09602-8 |2 doi | |
| 035 | |a (DE-627)1693836785 | ||
| 035 | |a (DE-599)KXP1693836785 | ||
| 035 | |a (OCoLC)1341313621 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Gonzalez-Duarte, Alejandra |e VerfasserIn |0 (DE-588)1198134224 |0 (DE-627)1680039598 |4 aut | |
| 245 | 1 | 0 | |a Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis |c Alejandra González-Duarte, John L. Berk, Dianna Quan, Michelle L. Mauermann, Hartmut H. Schmidt, Michael Polydefkis, Márcia Waddington-Cruz, Mitsuharu Ueda, Isabel M. Conceição, Arnt V. Kristen, Teresa Coelho, Cécile A. Cauquil, Céline Tard, Madeline Merkel, Emre Aldinc, Jihong Chen, Marianne T. Sweetser, Jing Jing Wang, David Adams |
| 264 | 1 | |c 2020 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published: 14 November 2019 | ||
| 500 | |a Gesehen am 02.04.2020 | ||
| 520 | |a Hereditary transthyretin-mediated (hATTR) amyloidosis is a progressive, debilitating disease often resulting in early-onset, life-impacting autonomic dysfunction. The effect of the RNAi therapeutic, patisiran, on autonomic neuropathy manifestations in patients with hATTR amyloidosis with polyneuropathy in the phase III APOLLO study is reported. Patients received patisiran 0.3 mg/kg intravenously (n = 148) or placebo (n = 77) once every 3 weeks for 18 months. Patisiran halted or reversed polyneuropathy and improved quality of life from baseline in the majority of patients. At baseline, patients in APOLLO had notable autonomic impairment, as demonstrated by the Composite Autonomic Symptom Score-31 (COMPASS-31) questionnaire and Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) questionnaire autonomic neuropathy domain. At 18 months, patisiran improved autonomic neuropathy symptoms compared with placebo [COMPASS-31, least squares (LS) mean difference, − 7.5; 95% CI: − 11.9, − 3.2; Norfolk QOL-DN autonomic neuropathy domain, LS mean difference, − 1.1; − 1.8, − 0.5], nutritional status (modified body mass index, LS mean difference, 115.7; − 82.4, 149.0), and vasomotor function (postural blood pressure, LS mean difference, − 0.3; − 0.5, − 0.1). Patisiran treatment also led to improvement from baseline at 18 months for COMPASS-31 (LS mean change from baseline, − 5.3; 95% CI: − 7.9, − 2.7) and individual domains, orthostatic intolerance (− 4.6; − 6.3, − 2.9) and gastrointestinal symptoms (− 0.8; − 1.5, − 0.2). Rapid worsening of all study measures was observed with placebo, while patisiran treatment resulted in stable or improved scores compared with baseline. Patisiran demonstrates benefit across a range of burdensome autonomic neuropathy manifestations that deteriorate rapidly without early and continued treatment. | ||
| 534 | |c 2019 | ||
| 700 | 1 | |a Kristen, Arnt |d 1974- |e VerfasserIn |0 (DE-588)123480965 |0 (DE-627)706314530 |0 (DE-576)293726876 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of neurology |d [Darmstadt] : Steinkopff, 1974 |g 267(2020), 3, Seite 703-712 |h Online-Ressource |w (DE-627)242065155 |w (DE-600)1421299-7 |w (DE-576)065026500 |x 1432-1459 |7 nnas |a Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis |
| 773 | 1 | 8 | |g volume:267 |g year:2020 |g number:3 |g pages:703-712 |g extent:10 |a Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis |
| 787 | 0 | 8 | |i Errata |a Gonzalez-Duarte, Alejandra |t Correction to: analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis |d 2020 |w (DE-627)1693837048 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00415-019-09602-8 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200402 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 123480965 |a Kristen, Arnt |m 123480965:Kristen, Arnt |d 910000 |d 910100 |d 50000 |e 910000PK123480965 |e 910100PK123480965 |e 50000PK123480965 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 10 | ||
| 999 | |a KXP-PPN1693836785 |e 3617672035 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"person":[{"given":"Alejandra","role":"aut","roleDisplay":"VerfasserIn","display":"Gonzalez-Duarte, Alejandra","family":"Gonzalez-Duarte"},{"family":"Kristen","roleDisplay":"VerfasserIn","role":"aut","given":"Arnt","display":"Kristen, Arnt"}],"relHost":[{"origin":[{"publisherPlace":"[Darmstadt] ; Berlin ; Heidelberg [u.a.] ; Darmstadt ; Heidelberg","dateIssuedKey":"1974","dateIssuedDisp":"1974-","publisher":"Steinkopff ; Springer ; Steinkopff [u.a.] ; Springer-Medizin-Verl."}],"physDesc":[{"extent":"Online-Ressource"}],"language":["eng","ger"],"disp":"Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosisJournal of neurology","title":[{"title":"Journal of neurology","title_sort":"Journal of neurology"}],"id":{"eki":["242065155"],"zdb":["1421299-7"],"issn":["1432-1459"]},"pubHistory":["Volume 207, issue 1 (March 1974)-"],"type":{"bibl":"periodical","media":"Online-Ressource"},"part":{"pages":"703-712","extent":"10","year":"2020","text":"267(2020), 3, Seite 703-712","issue":"3","volume":"267"},"recId":"242065155","note":["Gesehen am 14.03.25","Ungezählte Beil.: Supplement"]}],"name":{"displayForm":["Alejandra González-Duarte, John L. Berk, Dianna Quan, Michelle L. Mauermann, Hartmut H. Schmidt, Michael Polydefkis, Márcia Waddington-Cruz, Mitsuharu Ueda, Isabel M. Conceição, Arnt V. Kristen, Teresa Coelho, Cécile A. Cauquil, Céline Tard, Madeline Merkel, Emre Aldinc, Jihong Chen, Marianne T. Sweetser, Jing Jing Wang, David Adams"]},"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"2020"}],"id":{"eki":["1693836785"],"doi":["10.1007/s00415-019-09602-8"]},"physDesc":[{"extent":"10 S."}],"title":[{"title":"Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis","title_sort":"Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1693836785","note":["Published: 14 November 2019","Gesehen am 02.04.2020"]} | ||
| SRT | |a GONZALEZDUANALYSISOF2020 | ||